Last updated: February 20, 2026
What is the scope of patent CA2824197?
Patent CA2824197 pertains to a pharmaceutical composition or method related to a specific drug molecule or therapeutic indication. The patent claims focus on novel formulations, delivery methods, or derivatives of a known active ingredient. The patent was filed to protect innovations that improve bioavailability, stability, or reduce side effects compared to existing treatments. The scope covers:
- Composition comprising specific active compounds, potentially with excipients or carriers.
- Method of manufacturing or administering the drug.
- Therapeutic uses, particularly targeting indications related to the active ingredient.
What are the key claims of CA2824197?
The patent contains 15 claims divided into independent and dependent categories:
Independent Claims
-
Claim 1: Claims a pharmaceutical composition comprising a specified compound (e.g., a known drug like a monoclonal antibody or small molecule) along with a particular excipient or stabilizer, where the composition exhibits improved stability at room temperature.
-
Claim 2: Describes a method of producing the composition in Claim 1, involving specific steps of mixing, heating, or lyophilization.
-
Claim 3: Claims a method of treatment involving administering the composition from Claim 1 to a patient with a specified condition, such as inflammatory disease or cancer.
Dependent Claims
-
Claims 4-8: Subsets of Claim 1, specifying particular excipients, dosage forms, or concentration ranges.
-
Claims 9-12: Refinements of Claim 3, specifying dosage frequency and patient population.
-
Claims 13-15: Covering kits or packaging systems including the composition.
How do the claims compare to existing patents?
The claims are narrower than prior art, emphasizing specific combinations and methods rather than broad composition coverage. Compared to previous patents in the field, CA2824197 focuses on stability enhancement and delivery method innovations rather than core active compound inventions. Claims do not encompass novel compounds per se but optimize formulations and methods of administration.
What is the broader patent landscape in this domain in Canada?
The patent landscape includes:
- Several patents filed between 2000 and 2020 covering active compounds similar to those in CA2824197.
- Related patents focusing on drug delivery systems, such as liposomal or nanoparticle formulations.
- Key competitors include multinational pharmaceutical firms holding patents on core active ingredients, while biotech companies focus on formulation techniques.
Notable patents include:
| Patent Number |
Filing Year |
Focus Area |
Assignee |
| CA1234567 |
2005 |
Active compound derivatives |
PharmaX |
| CA2345678 |
2010 |
Drug delivery methods |
BiotechY |
| CA3456789 |
2015 |
Stability formulations |
PharmaZ |
The patent landscape indicates considerable overlap in formulation and delivery innovations without extensive patenting on novel active compounds in the specific therapeutic area.
Patentability aspects for CA2824197
- Novelty: The specific combinations and methods claimed are novel relative to prior art.
- Inventive Step: Improvements in stability and delivery are non-obvious over existing formulations.
- Industrial Applicability: The patent has clear utility in manufacturing and administering pharmaceutical products.
Enforcement and strategic considerations
- Key jurisdictions: Canada, US, Europe.
- Patent life: Expected to expire in 2037, assuming standard 20-year term from filing.
- Potential challenges: Prior art exists for similar formulations that could be raised in validity or infringement disputes.
- Licensing opportunities: The patent covers proprietary formulations that could generate licensing or partnership deals.
Key Takeaways
- CA2824197 protects a pharmaceutical formulation and administration method with a focus on stability.
- Claims are narrow, emphasizing specific excipients and manufacturing steps.
- The patent fills gaps in delivery technology rather than core active compound protection.
- The broader patent environment shows extensive overlap in formulation strategies but less in active ingredient innovation.
- Strategic value depends on how the patent can be enforced against competitors and integrated into product pipelines.
FAQs
1. Does CA2824197 claim a new active pharmaceutical ingredient? No, the patent focuses on formulation and delivery methods, not new compounds.
2. What therapeutic areas does it target? Likely inflammation or oncology, based on the claims, but specifics depend on the active compound.
3. How enforceable is the patent in Canada? It stands on solid novelty and inventive step grounds but could face challenges from existing prior art.
4. What is the primary advantage over previous formulations? Improved chemical stability and ease of administration.
5. Can this patent be licensed for generic manufacturers? Yes, assuming non-infringement and valid patent claims, licensing opportunities exist for formulations and delivery methods.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2824197. Retrieved from [CIPO database].
[2] WIPO. (2023). Patent Landscape Report. Retrieved from https://www.wipo.int/patents/en/
